Less: net loss attributable to noncontrolling interest Less: Net loss attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Stock conversion ratio Redeemable Non Controlling Interest Exchange Agreement Stock Conversion Ratio Redeemable non controlling interest exchange agreement stock conversion ratio. vTv Therapeutics LLC V Tv L L C [Member] vTv LLC. Statistical Measurement Statistical Measurement [Domain] Research and development Research and Development Expense Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Related Party Transaction [Line Items] Related Party Transaction [Line Items] License Agreement Obligations License Agreement Obligations [Domain] License agreement obligations. Non-qualified stock option awards expiration term Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Award Type Award Type [Domain] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Research and Development Research and Development Expense, Policy [Policy Text Block] Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Equity investment with readily determinable fair value: Equity Investments With Readily Determinable Fair Value Equity investments with readily determinable fair value. Equity Securities Without Readily Determinable Fair Value [Line Items] Equity Securities without Readily Determinable Fair Value [Line Items] Options exercisable, weighted average remaining contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Collaborative arrangement, contingent consideration Collaborative Arrangement, Contingent Consideration Transferred, Aggregate Share Value Collaborative Arrangement, Contingent Consideration Transferred, Aggregate Share Value Decrease/(Increase) in vTv Therapeutics Inc. accumulated deficit for purchase of LLC Units as a result of common stock issuances Consolidation Changes Wholly Owned Subsidiary Parent Ownership Interest Changes Purchase Of Interest By Parent Consolidation changes wholly owned subsidiary parent ownership interest changes purchase of interest by parent. Commitments and contingencies Commitments and Contingencies Expected volatility Measurement Input, Price Volatility [Member] Lessee, Operating Lease, Liability, Payment, Due [Abstract] Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Discount rate Notes Receivable, Discount Rate Notes Receivable, Discount Rate Options exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Stockholders' Deficit Equity [Text Block] Proceeds from sale of Class A common stock, net of offering costs Proceeds from Issuance of Common Stock Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Axis] MacAndrews & Forbes Incorporated Mac Andrews And Forbes Incorporated [Member] MacAndrews and Forbes Incorporated. Income Taxes Income Tax Disclosure [Text Block] Description of Business, Basis of Presentation and Going Concern Business Description and Basis of Presentation [Text Block] Contract liabilities Increase (Decrease) in Contract with Customer, Liability Type 2 Diabetes Type Two Diabetes [Member] Type 2 diabetes. Noncontrolling Interest [Abstract] Noncontrolling Interest [Abstract] Customer [Axis] Customer [Axis] Current liabilities: Liabilities, Current [Abstract] Minority Interest [Table] Noncontrolling Interest [Table] Lessee, operating lease, termination period Lessee, Operating Lease, Termination Period Lessee, Operating Lease, Termination Period Organization Consolidation And Presentation Of Financial Statements [Line Items] Organization Consolidation And Presentation Of Financial Statements [Line Items] Organization consolidation and presentation of financial statements. Net loss per share of vTv Therapeutics Inc. Class A Common Stock, diluted (in usd per share) Earnings Per Share, Diluted Change in fair value of investments Change in fair value of investments Unrealized Gain (Loss) on Investments Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Awards outstanding, Beginning balance (in shares) Awards outstanding, Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Redeemable noncontrolling interest Beginning balance Ending balance Redeemable Noncontrolling Interest, Equity, Carrying Amount Trading Symbol Trading Symbol Granted (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted average grant date fair value of options granted (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Net loss attributable to vTv Therapeutics Inc. Net loss Net Income (Loss) Total current liabilities Liabilities, Current Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Leases Lessee, Operating Leases [Text Block] Liabilities, Redeemable Noncontrolling Interest and Stockholders’ Deficit Liabilities and Equity [Abstract] Net Change in fair value included in earnings Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings Notes receivable recorded at fair value from collaboration partner Notes Receivable from Collaborators Notes Receivable from Collaborators Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Stockholders’ deficit: Equity, Attributable to Parent [Abstract] Concentration Risk Benchmark Concentration Risk Benchmark [Domain] Contract liabilities, net of current portion Contract with Customer, Liability Cantor Fitzgerald Cantor Fitzgerald [Member] Cantor fitzgerald member. Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Non-qualified stock option awards vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Class B Common Stock Common Class B [Member] Novo License Agreement Novo License Agreement [Member] Novo license agreement. Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Equity Components Equity Components [Axis] Financial Instruments Financial Instruments [Domain] Exercise price of warrants or rights (in usd per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Redeemable Noncontrolling Interest Redeemable Noncontrolling Interests [Member] Redeemable noncontrolling interests. Phase 2 MRCT Phase Two Multi Regional Clinical Trial [Member] Phase two multi-regional clinical trial. Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Entity Small Business Entity Small Business Local Phone Number Local Phone Number Accounts receivable Increase (Decrease) in Accounts Receivable Forecast Forecast [Member] Transaction Transaction [Domain] Measurement Frequency Measurement Frequency [Axis] Common stock warrants Warrant [Member] Operating lease liabilities, net of current portion Operating Lease, Liability, Noncurrent Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Depreciation expense Depreciation Proceeds from G42 Promissory Note early redemption related to sale of Class A common stock to collaboration partner Proceeds from Repayment of Loans to Purchase Common Stock Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Transaction Type Transaction Type [Axis] Income Statement Location Income Statement Location [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Redemption amount of noncontrolling interest Redeemable Noncontrolling Interest Temporary Equity Redemption Value Redeemable noncontrolling interest temporary equity redemption value. Schedule of Maturities of Lease Liabilities for Operating Leases Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Shares sold (in shares) Sale of Stock, Number of Shares Issued in Transaction Risk-free interest rate Measurement Input, Risk Free Interest Rate [Member] Commitment Contingency And Related Party Transactions [Abstract] Commitment Contingency And Related Party Transactions [Abstract] Commitment, Contingency And Related Party Transactions [Abstract] Product and Service Product and Service [Domain] Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Research and development Research and Development Expense [Member] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Sale of stock, consideration received on transaction, gross Sale of Stock, Consideration Received on Transaction, Gross Sale of Stock, Consideration Received on Transaction, Gross Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type Award Type [Axis] Document Quarterly Report Document Quarterly Report Collaboration revenue recognized Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer Interest expense Interest Expense Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Loss from G42 Promissory Note early redemption Gain (Loss) on Extinguishment of Debt General and administrative General and Administrative Expense [Member] Related-Party Transactions Related Party Transactions Disclosure [Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Change in redemption value of noncontrolling interest Temporary Equity, Change In Redemption Value Temporary Equity, Change In Redemption Value Entity File Number Entity File Number Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Current portion of operating lease liabilities Operating Lease, Liability, Current Entity Shell Company Entity Shell Company 2026 Lessee, Operating Lease, Liability, to be Paid, Year Three Long-term investments Long-Term Investments Recently Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Commitments and Contingencies. CinRx Warrants CinRx Warrants [Member] CinRx Warrants Counterparty Name [Domain] Counterparty Name [Domain] Total cash and cash equivalents, beginning of period Total cash and cash equivalents, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two Sale of stock, price per share (in usd per shares) Sale of Stock, Price Per Share Interest income Investment Income, Interest Anteris Bio Inc Anteris Bio Inc [Member] Anteris Bio, Inc. Amount of cash savings percentage Percentage Of Amount Of Cash Savings Percentage of amount of cash savings. Collaborate arrangement, contingent consideration transferred, cash Collaborate Arrangement, Contingent Consideration Transferred, Cash Collaborate Arrangement, Contingent Consideration Transferred, Cash Current portion of contract liabilities Contract with Customer, Liability, Current Security Exchange Name Security Exchange Name Type 1 Diabetes Type One Diabetes [Member] Type 1 diabetes. Equity securities with readily determinable fair value - Total Assets, Fair Value Disclosure Sale of stock, consideration received on transaction Sale of Stock, Consideration Received on Transaction Collaboration Agreements Collaborative Arrangement Disclosure [Text Block] Stock Option Common stock options granted under the Plan Employee Stock Option [Member] Investments Investment, Policy [Policy Text Block] ATM Offering At The Market Offering [Member] At the market offering. G42 Investments G42 Investments [Member] G42 Investments Class A Common Stock Common Class A [Member] Weighted average period to recognize unrecognized share-based compensation cost Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Redeemable Noncontrolling Interest Noncontrolling Interest Disclosure [Text Block] Stock Conversion Description Stock Conversion Description [Axis] Income Taxes [Table] Income Taxes [Table] Income taxes. Maximum Maximum [Member] Document Type Document Type Schedule Of Earnings Per Share [Line Items] Schedule Of Earnings Per Share [Line Items] Schedule Of Earnings Per Share [Line Items] Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Subsequent Event [Table] Subsequent Event [Table] Share-Based Compensation Share-Based Payment Arrangement [Text Block] Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Customer Customer Concentration Risk [Member] Shares held by related party (in shares) Investment Owned, Balance, Shares Accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Income Statement [Abstract] Income Statement [Abstract] Current deposits Deposits Assets, Current Issuance of Class A Common Stock to Collaboration Partner (in shares) Stock Issued During Period, Shares, New Issues Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Title of 12(b) Security Title of 12(b) Security Non-cash interest income Interest Income, Operating Related Party Related Party, Type [Domain] Numerator: Net Income (Loss) Attributable to Parent [Abstract] Class Of Stock [Line Items] Class of Stock [Line Items] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number CinRx Pharma, LLC CinRx Pharma, LLC [Member] CinRx Pharma, LLC Other Commitments Other Commitments [Domain] Statistical Measurement Statistical Measurement [Axis] Financial Instrument Financial Instrument [Axis] Entity Interactive Data Current Entity Interactive Data Current Receivables, fair value disclosure Receivables, Fair Value Disclosure Organization Consolidation And Presentation Of Financial Statements [Table] Organization Consolidation And Presentation Of Financial Statements [Table] Organization Consolidation And Presentation Of Financial Statements [Table] Number of days used to determine exchange value based on weighted average price of Class A common stock Period Used To Determine Exchange Value Based On Weighted Average Price Of Class Common Stock Period used to determine exchange value based on weighted average price of Class A common stock. Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Non-cash activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Less: imputed interest Operating Leases Imputed Interest Operating leases imputed interest. Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] JDRF J D R F International [Member] JDRF international. Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets: Assets, Current [Abstract] Summary of Net Income Attributable to Vtv Therapeutics Inc Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table Text Block] Leases [Abstract] Leases [Abstract] Entity Address, State or Province Entity Address, State or Province Counterparty Name [Axis] Counterparty Name [Axis] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Schedule Of Related Party Transactions By Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Common stock, shares outstanding (in shares) Beginning balance, shares (in shares) Ending balance, shares (in shares) Common Stock, Shares, Outstanding Change in redemption value of noncontrolling interest Change in redemption value of noncontrolling interest Noncontrolling Interest, Change in Redemption Value Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] M&F TTP Holdings LLC M F T T P Holdings L L C [Member] M&F TTP Holdings LLC. Conversion of Stock, Name Conversion of Stock, Name [Domain] Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward] Increase (Decrease) in Temporary Equity [Roll Forward] Common stock par value (in usd per share) Common Stock, Par or Stated Value Per Share Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Class of Stock Class of Stock [Domain] Assets: Equity Securities, FV-NI, Current Customer [Domain] Customer [Domain] Net loss attributable to vTv Therapeutics Inc. common shareholders Net loss attributable to common shareholders of vTv Therapeutics Inc., basic Net Income (Loss) Available to Common Stockholders, Basic Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Collaborative Arrangements Collaborative Arrangement [Member] Present value of lease liabilities Operating Lease, Liability Potential milestone payment Potential Milestone Payment Potential milestone payment. Measurement Input Type Measurement Input Type [Domain] Total liabilities Liabilities Equity method investments, ownership percentage Investment Ownership Percentage Investment ownership percentage. Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Schedule of Equity Investments with and without Readily Determinable Fair Values Assessed Equity Securities With And Without Readily Determinable Fair Value Table [Table Text Block] Tabular disclosure of investment in equity security with and without readily determinable fair value. Options vested and expected to vest (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Measurement Frequency Measurement Frequency [Domain] Common stock, capital shares reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Contract liabilities, net of current portion Contract with Customer, Liability, Noncurrent Fair Value Of Assets And Liabilities Measured On Recurring Basis [Table] Fair Value Of Assets And Liabilities Measured On Recurring Basis [Table] Fair value of assets and liabilities measured on recurring basis table. Related Party Transaction [Domain] Related Party Transaction [Domain] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Subsequent Event [Line Items] Subsequent Event [Line Items] Common stock value Common Stock, Value, Issued General and administrative General and Administrative Expense Potential development and regulatory milestone payments Potential Development And Regulatory Milestone Payments Receivable Potential development and regulatory milestone payments receivable. Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Total current assets Assets, Current Preferred Stock Preferred Stock [Member] Satisfaction of Milestone Payment Satisfaction Of Milestone Payment [Member] Satisfaction of milestone payment. Discount on note receivable Collaborative Arrangement, Note Receivable, Discount Paid Collaborative Arrangement, Note Receivable, Discount Paid Income Taxes [Line Items] Income Taxes [Line Items] Income taxes. Other income (expense), net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items] Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items] Fair value of assets and liabilities measured on recurring basis. Expected dividend yield Measurement Input, Expected Dividend Rate [Member] Concentration risk percentage Concentration Risk, Percentage Beginning Balance Ending Balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Warrant liability, related party Warranty Liability Warranty Liability Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Class of Stock Class of Stock [Axis] Change in fair value of warrants, related party Change In Fair Value Of Warrants Related Party Change in fair value of warrants related party. Accounts payable and accrued expenses Accounts Payable and Accrued Liabilities, Current Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] CinRx Investment CinRx Investment [Member] CinRx Investment Total stockholders’ deficit attributable to vTv Therapeutics Inc. Beginning balance Ending balance Equity, Attributable to Parent Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Fair Value Measurement Inputs and Valuation Techniques Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Schedule Of Stock By Class [Table] Schedule of Stock by Class [Table] Concentration Risk Type Concentration Risk Type [Axis] Developmental and Regulatory Milestone Payment Developmental And Regulatory Milestone Payment [Member] Developmental and regulatory milestone payment. Subsequent Events [Abstract] Subsequent Events [Abstract] Loss before income taxes and noncontrolling interest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Inputs utilized in the valuation of warrants Warrants and Rights Outstanding, Measurement Input Equity investment without readily determinable fair values assessed under the measurement alternative: Equity Securities without Readily Determinable Fair Value, Amount Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Royalties receivable, period Collaborative Arrangement, Royalties Receivable, Period Collaborative Arrangement, Royalties Receivable, Period Entity Emerging Growth Company Entity Emerging Growth Company Thereafter Lessee, Operating Lease, Liability, to be Paid, After Year Four Lessee, Operating Lease, Liability, to be Paid, After Year Four Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Document Fiscal Period Focus Document Fiscal Period Focus 2024 Lessee, Operating Lease, Liability, to be Paid, Year One Antidilutive Securities Antidilutive Securities [Axis] 2027 Lessee, Operating Lease, Liability, to be Paid, Year Four Other Indication Other Indication [Member] Other indication. Awards outstanding, Beginning balance (in usd per share) Awards outstanding, Ending balance (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based compensation expense Share-Based Payment Arrangement, Noncash Expense Weighted Average Weighted Average [Member] Capital stock, shares authorized (in shares) Common Stock And Preferred Stock Shares Authorized Common stock and preferred stock shares authorized. Common Stock Common Stock [Member] Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Change Due to Net Income Attributable to Parent and Effects of Changes, Net Percentage of non-voting economic interest of vTv Therapeutics Inc in vTv LLC Percentage Of Non Voting Economic Interest By Parent Percentage of non voting economic interest by parent. City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Product and Service Product and Service [Axis] Net Loss per Share Earnings Per Share [Text Block] Income Statement Location Income Statement Location [Domain] Maximum funding percentage of research and development milestones Maximum Funding Percentage Of Research And Development Milestones Maximum funding percentage of research and development milestones. G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement [Member] G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement Document Fiscal Year Focus Document Fiscal Year Focus Minimum Minimum [Member] Denominator: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Property and equipment, net Property, Plant and Equipment, Net Summary of Stock Award Activity for the Period Share-Based Payment Arrangement, Option, Activity [Table Text Block] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Assets Assets [Abstract] Liabilities: Liabilities, Fair Value Disclosure Nonrelated Party Nonrelated Party [Member] Net loss before noncontrolling interest Net loss before noncontrolling interest Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Purchases / Issuance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Accumulated Deficit Retained Earnings [Member] Exchange of Redeemable Non controlling Interest To Class A Common Stock Exchange Of Redeemable Non Controlling Interest To Class A Common Stock [Member] Exchange of redeemable non controlling interest to class A common stock. Summary of Compensation Expense Related to Grants of Stock Options Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Total liabilities, redeemable noncontrolling interest and stockholders’ deficit Liabilities and Equity Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic (in usd per share) Earnings Per Share, Basic Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Unrecognized compensation cost related to non-vested share-based compensation arrangements Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Accounting Policies [Abstract] Accounting Policies [Abstract] Schedule Of Earnings Per Share [Table] Schedule Of Earnings Per Share [Table] Schedule Of Earnings Per Share [Table] Warrants, term Expected life of options in years Warrants and Rights Outstanding, Term Sales-based Milestones Payment Sales Based Milestones Payment [Member] Sales-based milestones payment. 2023 (remaining six months) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Number of securities called by warrants or rights (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Net loss attributable to common shareholders of vTv Therapeutics Inc., diluted Net Income (Loss) Available to Common Stockholders, Diluted Entity Address, City or Town Entity Address, City or Town Related Party Related Party [Member] Master Service Agreement Master Service Agreement [Member] Master Service Agreement Aggregate offering price Aggregate Offering Price Of Shares Aggregate offering price of shares. Sale of stock, consideration, receivables, payment term Sale Of Stock, Consideration, Receivable, Term Sale Of Stock, Consideration, Receivable, Term Options vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Document Transition Report Document Transition Report Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Summary of significant accounting policies. Common stock, shares authorized (in shares) Common Stock, Shares Authorized Proceeds from collection of notes receivable Proceeds from Collection of Notes Receivable Document Information [Table] Document Information [Table] Adjustments to transaction price for performance obligations Adjustments To Transaction Price For Performance Obligations Adjustments to transaction price for performance obligations. Percentage of non-voting economic interest of vTv Therapeutics Holdings LLC in vTv LLC Noncontrolling interest ownership percentage Percentage Of Non Voting Economic Interest Percentage of non voting economic interest. Noncontrolling Interest [Line Items] Noncontrolling Interest [Line Items] Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Related Party Transactions [Abstract] Related Party Transactions [Abstract] Measurement Input Type Measurement Input Type [Axis] Unaudited Interim Financial Information Unaudited Interim Financial Information Policy [Policy Text Block] Unaudited interim financial information policy. Current portion of notes payable Notes Payable, Current Common stock, value Common Stock, Value, Outstanding Conversion ratio Stockholders' Equity Note, Stock Split, Conversion Ratio LPC Purchase Agreement L P C Purchase Agreement [Member] LPC purchase agreement. Other Commitments Other Commitments [Axis] Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Net loss Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest Document Information [Line Items] Document Information [Line Items] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Forfeited (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Warrant liability, related party Warrant Liability Related Party [Member] Warrant liability, related party. Letter Agreement Warrants Letter Agreement Warrants [Member] Letter agreement warrants. Increase in shares authorized (in shares) Increase In Common Stock Shares Authorized Increase in common stock shares authorized. Share price (usd per share) Share Price Related Party Related Party, Type [Axis] Entity Registrant Name Entity Registrant Name Maximum contribution amount to clinical trial Maximum Sponsoring Contribution Amount Maximum sponsoring contribution amount. Warrants, fair value Warrants and Rights Outstanding Equity Securities Without Readily Determinable Fair Value [Table] Equity Securities without Readily Determinable Fair Value [Table] Cogna Cogna [Member] Cogna Document Period End Date Document Period End Date Summarizes the Conclusions Reached Regarding Fair Value Measurements Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Options exercisable (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Entity Central Index Key Entity Central Index Key Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Total share-based compensation expense Share-Based Payment Arrangement, Expense Income tax provision Income Tax Expense (Benefit) One Customer One Customer [Member] One Customer Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Commitments And Contingencies [Table] Commitments And Contingencies [Table] Commitments And Contingencies [Table] Revenue Revenue Benchmark [Member] Issuance of Class A common stock to collaboration partner, net of offering cost Stock issued during period Stock Issued During Period, Value, New Issues Equity [Abstract] Equity [Abstract] Remaining operating lease term Operating Lease, Weighted Average Remaining Lease Term Revenue Revenue from Contract with Customer, Excluding Assessed Tax Entity Entity [Domain] Amendment Flag Amendment Flag Legal Entity Legal Entity [Axis] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Repayment of notes payable Repayments of Notes Payable Weighted average incremental borrowing rate Operating Lease, Weighted Average Discount Rate, Percent Sales / Repurchases Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Summary of Contract Liabilities Related to Company's Collaboration Agreements Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] License and Technology Transfer Services of Chemistry and Manufacturing Know-How License And Technology Transfer Services Of Chemistry And Manufacturing Know How [Member] License and technology transfer services of chemistry and manufacturing know-how. Operating expenses: Operating Expenses [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Additional paid-in capital Additional Paid in Capital, Common Stock Additional Paid-in Capital Additional Paid-in Capital [Member] Total assets Assets Due to related parties, monthly amount Due To Related Parties, Monthly Amount Due To Related Parties, Monthly Amount G42 Promissory Note receivable Notes Receivable, Current Notes Receivable, Current Cover [Abstract] Cover [Abstract] Options vested and expected to vest, weighted average remaining contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Subsequent Events Subsequent Events [Text Block] Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Remaining available stock value Remaining Availability Stock Issued During Period Value New Issues Remaining availability under our controlled equity offering sales agreement Total lease payments Lessee, Operating Lease, Liability, to be Paid License Agreement Obligations License Agreement Obligations [Axis] License agreement obligations. Unrecognized amount of transaction price allocated to performance obligation Revenue, Remaining Performance Obligation, Amount Total operating expenses Operating Expenses Net increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Lessee, operating lease, renewal term Lessee, Operating Lease, Renewal Term Equity Component Equity Component [Domain] Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Hangzhou Zhongmei Huadong Pharmaceutical Company Limited [Member] Hangzhou Zhongmei Huadong Pharmaceutical Company Limited. Accounts and financing receivable, after allowance for credit loss Accounts and Financing Receivable, after Allowance for Credit Loss, Current Scenario [Axis] Scenario [Axis] Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Concentration Risk Type Concentration Risk Type [Domain] Operating loss Operating Income (Loss) Concentration Risk Benchmark Concentration Risk Benchmark [Axis] Related Party Transaction [Axis] Related Party Transaction [Axis] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Statement [Line Items] Statement [Line Items] Scenario [Domain] Scenario [Domain] Ownership percentage of majority owner Ownership Percentage Of Majority Owner Ownership percentage of majority owner. Reneo Reneo Pharmaceuticals Inc [Member] Reneo Pharmaceuticals Inc. Redeemable Noncontrolling Interest Noncontrolling Interest [Member]